Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment

被引：26

作者：

Abou-El-Enein, Mohamed ^{[1
]}

Cathomen, Toni ^{[2
,3
]}

Ivics, Zoltan ^{[4
]}

June, Carl H. ^{[5
]}

Renner, Matthias ^{[4
]}

Schneider, Christian K. ^{[6
]}

Bauer, Gerhard ^{[7
]}

机构：

[1] Charite Univ Med Berlin, Berlin Brandenburg Ctr Regenerat Therapies BCRT, Berlin, Germany

[2] Univ Freiburg, Med Ctr, Inst Transfus Med & Gene Therapy, Freiburg, Germany

[3] Univ Freiburg, Fac Med, Freiburg, Germany

[4] Paul Ehrlich Inst, Div Med Biotechnol, Langen, Germany

[5] Univ Penn, Ctr Cellular Therapies, Perelman Sch Med, Philadelphia, PA 19104 USA

[6] Med & Healthcare Prod Regulatory Agcy, NIBSC, S Mimms, Herts, England

[7] Univ Calif Davis, IRC, Sacramento, CA 95817 USA

来源：

CELL STEM CELL | 2017年 / 21卷 / 04期

关键词：

TECHNOLOGIES; NUCLEASES;

D O I：

10.1016/j.stem.2017.09.007

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

As genome editing rapidly progresses toward the realization of its clinical promise, assessing the suitability of current tools and processes used for its benefit-risk assessment is critical. Although current regulations may initially provide an adequate regulatory framework, improvements are recommended to overcome several existing technology-based safety and efficacy issues.

引用

页码：427 / 430

页数：4

共 50 条

[41] Benefit-risk assessment of raloxifene in postmenopausal osteoporosis
Cranney, A
Adachi, JD
[J]. DRUG SAFETY, 2005, 28 (08) : 721 - 730
[42] A benefit-risk assessment of caffeine as an analgesic adjuvant
Zhang, WY
[J]. DRUG SAFETY, 2001, 24 (15) : 1127 - 1142
[43] Benefit-risk assessment for binary diagnostic tests
Bai, Tianyu
Huang, Lan
Li, Meijuan
Tiwari, Ram
[J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (05) : 760 - 775
[44] On a Stepwise Quantitative Approach for Benefit-Risk Assessment
Weili He
Yaxuan Sun
Qing Li
Sabrina Wan
[J]. Therapeutic Innovation & Regulatory Science, 2017, 51 : 625 - 634
[45] Benefit-risk assessment of sirolimus in renal transplantation
Kuypers, DRJ
[J]. DRUG SAFETY, 2005, 28 (02) : 153 - 181
[46] Benefit-Risk Assessment of Sirolimus in Renal Transplantation
Dirk R.J. Kuypers
[J]. Drug Safety, 2005, 28 : 153 - 181
[47] Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis
Helmut Schmidt
Barry G. Woodcock
Gerd Geisslinger
[J]. Drug Safety, 2004, 27 : 185 - 196
[48] Bayesian Approach to Personalized Benefit-Risk Assessment
Cui, Shiqi
Zhao, Yueqin
Tiwari, Ram C.
[J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (03): : 316 - 324
[49] Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis
Schmidt, H
Woodcock, BG
Geisslinger, G
[J]. DRUG SAFETY, 2004, 27 (03) : 185 - 196
[50] Benefit-risk assessment of zaleplon in the treatment of insomnia
Barbera, J
Shaprio, C
[J]. DRUG SAFETY, 2005, 28 (04) : 301 - 318

← 1 2 3 4 5 →